Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND3 | P30281 | 7/20 | 0.47 |
| ▸ | CDK4 | P11802 | 7/20 | 0.47 |
| ▸ | CCND1 | P24385 | 7/20 | 0.47 |
| ▸ | CCND2 | P30279 | 6/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16285679 | 0.91 | CCND3 (0.46) | CCND3CDK4CCND1CCND2FYN | |
| SCHEMBL16285713 | 0.89 | CDK4 (0.46) | CCND3CDK4CCND1CCND2FYN | |
| SCHEMBL16285700 | 0.89 | CDK4 (0.46) | CCND3CDK4CCND1CCND2FYN | |
| SCHEMBL16285663 | 0.89 | CDK4 (0.42) | CCND3CDK4CCND1CCND2KDM1A | |
| SCHEMBL16285699 | 0.89 | CDK4 (0.46) | CCND3CDK4CCND1CCND2FYN | |
| SCHEMBL16285692 | 0.89 | CDK4 (0.46) | CCND3CDK4CCND1CCND2FYN | |
| SCHEMBL16285682 | 0.87 | CDK4 (0.45) | CCND3CDK4CCND1CCND2FYN | |
| SCHEMBL16285684 | 0.87 | CDK4 (0.45) | CCND3CDK4CCND1CCND2FYN | |
| SCHEMBL16285677 | 0.87 | JAK2 (0.49) | CCND3CDK4CCND1CCND2FYN | |
| SCHEMBL16285685 | 0.87 | FYN (0.47) | CCND3CDK4CCND1CCND2FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | CCND3 4558/4885CDK4 2824/4885CCND1 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.